Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study)

  • Rogério A. Costa
  • Rodrigo Jorge
  • Daniela Calucci
  • Luiz A. S. MeloJr.
  • José A. Cardillo
  • Ingrid U. Scott
Clinical Investigation

DOI: 10.1007/s00417-007-0557-x

Cite this article as:
Costa, R.A., Jorge, R., Calucci, D. et al. Graefes Arch Clin Exp Ophthalmol (2007) 245: 1273. doi:10.1007/s00417-007-0557-x

Abstract

Background

A novel alternative for combined treatment using verteporfin photodynamic therapy (PDT) has emerged as preliminary safety and efficacy data of the intravitreal use of the anti-angiogenic bevacizumab became available. In the current study we investigate the feasibility of intravitreal bevacizumab combined with verteporfin PDT for the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).

Methods

A single-centre, prospective, open-label study of 11 patients with documented CNV progression after PDT treatment who underwent combined PDT and intravitreal injection of 1.5 mg of bevacizumab was undertaken. Standardized ophthalmic evaluation was performed at baseline and at weeks 1, 2, 12 and 24. Clinical evidence of complications and changes in logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity (BCVA) using Early Treatment Diabetic Retinopathy Study (ETDRS) charts and in fluorescein leakage from CNV were evaluated.

Results

The mean (±SD) age of the 11 patients was 74 (±5) years. Seven eyes had been treated with one previous PDT session and four eyes had two previous PDT sessions. The mean baseline logMAR ETDRS BCVA was 1.031 (Snellen equivalent, 20/200−2). At follow-up weeks 1, 2, 12 and 24, the mean logMAR ETDRS BCVA (Snellen equivalent) was 0.944 (20/160−2), 0.924 (20/160−1), 0.882 (20/160+1), and 0.933 (20/160−2), respectively. The change in BCVA from baseline was significant at each study follow-up interval (P ≤ 0.001); at 12 and 24 weeks, the mean change in BCVA from baseline was an improvement of 1.49 and of 0.98 ETDRS line, respectively. Fluorescein leakage from CNV was absent in all eyes at week 12. One additional treatment session was required in seven (63.6%) eyes at week 24 due to recurrent fluorescein leakage from CNV (“minimum” [<50% of the leaking area noted at baseline], n = 4; and “moderate” [>50% of the leaking area noted at baseline], n = 3). No progression of the neovascular lesion was observed at week 24. No safety issues were identified throughout the period of the study.

Conclusions

The overall changes in vision and fluorescein leakage from CNV throughout the study suggest that a possible synergistic effect may arise from the combination of intravitreal bevacizumab with verteporfin PDT for the treatment of neovascular AMD.

Keywords

AngiogenesisLaserNeovascularizationChoroidPegaptanibRanibizumabVascular endotelhial growth factor (VEGF)

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Rogério A. Costa
    • 1
    • 2
  • Rodrigo Jorge
    • 2
  • Daniela Calucci
    • 1
  • Luiz A. S. MeloJr.
    • 1
  • José A. Cardillo
    • 1
  • Ingrid U. Scott
    • 3
  1. 1.U.D.A.T. Macular Imaging & Treatment DivisionHospital de Olhos de AraraquaraAraraquaraBrazil
  2. 2.Retina and Vitreous Section, Department of Ophthalmology, School of Medicine of Ribeirão PretoUniversity of São PauloRibeirão PretoBrazil
  3. 3.Departments of Ophthalmology and Health Evaluation SciencesPenn State College of MedicineHersheyUSA